A biotechnology company is licensing five of its vaccines for cancer and infectious diseases to Regeneron Pharmaceuticals in a deal valued at nearly $1 billion. . . . → Read More: Regeneron Gains Cancer, Infectious Disease Immunotherapies
|
|||||
       
  |
A new business is underway to develop and commercialize treatments for Covid-19 and other diseases based on synthetic antibody proteins. . . . → Read More: New Company to Develop Synthetic Antibody Therapies  One comment - (Comments are closed)  Finance, Intellectual property, New products  biomedical, biotechnology, Covid-19, entrepreneurs, equity, genomics, investment, licensing, pharmaceuticals, venture capital 
A developer of synthetic bio-based products from engineered yeast cells is joining with an immunotherapy drug maker to produce a stable RNA Covid-19 vaccine. . . . → Read More: Joint Venture to Develop Stable RNA Covid-19 Vaccine Comments are closed Joint ventures/collaborations, New products biomedical, biotechnology, cancer, chemistry, Covid-19, licensing, life sciences, manufacturing, nanotechnology, pharmaceuticals, physical sciences 
A developer of inherited eye disease therapies is acquiring rights to the gene editing technology Crispr for treatments that work inside the eyes. . . . → Read More: Crispr Licensed for Eye Disease Gene Therapies Comments are closed Intellectual property, Joint ventures/collaborations biomedical, biotechnology, equity, Europe, genomics, investment, licensing, life sciences, pharmaceuticals 
A new company is underway developing more precise therapies for psychiatric and neurodegenerative diseases based on genetics and data science. . . . → Read More: Precision Neuroscience Company Starts-Up, Raises $500M One comment - (Comments are closed) Finance, Joint ventures/collaborations, New products biomedical, biotechnology, entrepreneurs, equity, Europe, genomics, investment, licensing, life sciences, mathematics, pharmaceuticals, physical sciences, psychiatric, university, venture capital 
A developer of delivery methods for gene therapies promising greater safety for patients is raising $26 million in its first venture funding round. . . . → Read More: Gene Therapy Delivery Company Gains $26M in Early Funds Comments are closed Finance, New products biomedical, biotechnology, chemistry, entrepreneurs, equity, genomics, investment, licensing, life sciences, materials science, nanotechnology, pharmaceuticals, physical sciences, preclinical, university, venture capital 
A company is developing a nasal spray for epilepsy symptoms with a cannabis extract delivered in nanoscale polymer particles to the brain. . . . → Read More: Delivery Tech Licensed for CBD Epilepsy Nasal Spray Comments are closed Intellectual property, New products biomedical, chemistry, engineering, licensing, life sciences, materials science, nanotechnology, pharmaceuticals, physical sciences, preclinical, U.K. 
A company developing a one-time treatment for HIV infections using the gene-editing technique Crispr says it received FDA clearance to begin a clinical trial. . . . → Read More: FDA Okays One-Time HIV Treatment Clinical Trial 2 comments - (Comments are closed) New products, Regulations biomedical, biotechnology, clinical trials, entrepreneurs, FDA, genomics, HIV, licensing, life sciences, pharmaceuticals, university 
A pharmaceutical company and developer of synthetic genomic materials are collaborating on discovery of therapeutic antibodies to treat a range of diseases. . . . → Read More: Pharma, Synthetic Bio Companies to Find Antibody Therapies Comments are closed Joint ventures/collaborations biomedical, biotechnology, chemistry, Europe, genomics, licensing, life sciences, pharmaceuticals, physical sciences 
A one year-old biotechnology company developing treatments for diseases of microglia cells in the brain, is raising $90 million in new venture funds. . . . → Read More: Biotech Start-Up Gains $90M for Neurodegenerative Diseases Comments are closed Finance, New products biomedical, biotechnology, entrepreneurs, equity, genomics, investment, licensing, life sciences, pharmaceuticals, preclinical, university, venture capital |
|
|||
|
Copyright © 2021 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
